52 Results for "

LDHA

" in MedChemExpress (MCE) Product Catalog:
Products (52)

52 Results for "LDHA" in MCE Product Catalog:

69
69 Publications Verification
Cat. No.: HY-W013032A
CAS No.: 565-73-1
Synonyms: Sodium oxamate
Research Areas:  

Cancer

Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
loading...
    loading...
69
69 Publications Verification
Cat. No.: HY-W013032
CAS No.: 471-47-6
Synonyms: Oxamidic acid
Category:  

Microorganisms

Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-100681
CAS No.: 1445879-21-9
Purity:  99.24%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-16214
CAS No.: 213971-34-7
Synonyms: LDHA Inhibitor FX11
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-100742A
CAS No.: 2003234-63-5
Purity:  99.73%
(R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-W040118
CAS No.: 568-80-9
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-100742
CAS No.: 1802977-61-2
Purity:  99.38%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

GNE-140 racemate (Compound 28) is an external racemization mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and it is also an interconformational isomer of GNE-140 (HY-118241). GNE-140 racemate is also an effective lactate dehydrogenase (LDH) inhibitor, with the IC50 values for LDHA and LDHB being 9 nM and 30 nM respectively. GNE-140 racemate can be used in cancer research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-139319
CAS No.: 227010-33-5
Purity:  99.88%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N4185
CAS No.: 61153-77-3
Licoflavone A is an orally active PTP1B/VEGFR-2 inhibitor, with an IC50 of 54.5 μM against PTP1B, an IC50 of 14.36 μM and a Kd of 142.38 nM against human VEGFR-2. Licoflavone A blocks the PI3K/AKT and MEK/ERK signaling pathways. Licoflavone A induces G1 phase cell cycle arrest, apoptosis via the intrinsic mitochondrial pathway (apoptosis), and inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of gastric cancer cells. Licoflavone A inhibits the proliferation of gastric cancer cells in vitro and in xenograft models. Licoflavone A reduces the expression levels of HIF-1α, GLUT1, LDHA, PKM2 and HK2 in hypoxic gastric cancer cells, decreases glucose uptake and suppresses glycolysis. Licoflavone A can be used in research related to gastric cancer, type 2 diabetes and obesity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111108
CAS No.: 1964515-43-2
Purity:  99.84%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18968
CAS No.: 1370290-34-8
Synonyms: LDHA-IN-4
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM .
loading...
    loading...
Cat. No.: HY-152261
CAS No.: 2891709-58-1
Purity:  99.2%
Research Areas:  

Cancer

MS6105 is a PROTAC degrader targeting LDHA and LDHB, with DC50 values of 38 nM and 74 nM for degrading LDHA and LDHB in PANC-1 cells, respectively, and no hook effect is observed at high concentrations. MS6105 inhibits the proliferation of pancreatic cancer cells, and no obvious toxicity is observed after intraperitoneal administration in mice. MS6105 can be used for pancreatic cancer-related research .
loading...
    loading...
Cat. No.: HY-124309
CAS No.: 1269802-97-2
Purity:  99.30%
Research Areas:  

Cancer

NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
loading...
    loading...
Cat. No.: HY-W984782
CAS No.: 523-64-8
Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
loading...
    loading...
Cat. No.: HY-156683
CAS No.: 2743436-86-2
Purity:  98.05%
Target:  

Lactate Dehydrogenase

Research Areas:  

Metabolic Disease

CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .
loading...
    loading...
Cat. No.: HY-100742B
CAS No.: 2003234-64-6
Purity:  99.07%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

(S)-GNE-140 (Compound 30-S) is the S-enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with IC50 values of 55 nM for LDHA and 140 nM for LDHB. (S)-GNE-140 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-176798
CAS No.: 1964516-64-0
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
loading...
    loading...
Cat. No.: HY-RS07571
Research Areas:  

Others

LDHA Human Pre-designed siRNA Set A contains three designed siRNAs for LDHA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-178461
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-175230
CAS No.: 3084810-37-4
Research Areas:  

Cancer

ZG-2492 is an orally active LDHA inhibitor with an IC50 of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .
loading...
    loading...